DrugPatentWatch Database Preview
RYTARY Drug Profile
When do Rytary patents expire, and when can generic versions of Rytary launch?
Rytary is a drug marketed by Impax Labs Inc and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.
This drug has thirty-five patent family members in fourteen countries.
The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
Summary for RYTARY
International Patents: | 35 |
US Patents: | 9 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 3 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for RYTARY |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RYTARY |
DailyMed Link: | RYTARY at DailyMed |

Pharmacology for RYTARY
Drug Class | Aromatic Amino Acid |
US Patents and Regulatory Information for RYTARY
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-002 | Jan 7, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-003 | Jan 7, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-004 | Jan 7, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-001 | Jan 7, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for RYTARY
Drugname | Dosage | Strength | RLD | Date |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsules | 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg | ➤ Subscribe | ➤ Sign Up |
➤ Subscribe | Extended-release Capsules | 61.25 mg/245 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for RYTARY
Country | Document Number | Estimated Expiration |
---|---|---|
South Korea | 20150133854 | ➤ Sign Up |
European Patent Office | 2921170 | ➤ Sign Up |
South Korea | 101569604 | ➤ Sign Up |
Spain | 2606463 | ➤ Sign Up |
Country | Document Number | Estimated Expiration |